Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brimonidine Intravitreal Implant in Retinitis Pigmentosa
NCT00661479Phase 2Completed
- Sponsor
- Allergan
- Start
- Jul 2008
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, double-blind trial of brimonidine in retinitis pigmentosa (RP) (4 arms), sponsored by Allergan. Primary endpoints: Best Corrected Visual Acuity at Month 6 and Adverse Events at 12 months. Started Jul 2008; status: completed.
02
Drugs
brimonidine
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT00661479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00661479.